or Try an Advanced Search...

    Technical Analysis for TSHA - Taysha Gene Therapies, Inc.

    Grade Last Price % Change Price Change
    F 2.26 0.89% 0.02
    TSHA closed up 0.89 percent on Monday, July 1, 2024, on approximately normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical TSHA trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Pocket Pivot Bullish Swing Setup 0.89%
    Volume Surge Other 0.89%
    Lower Bollinger Band Walk Weakness 0.89%
    Older End-of-Day Signals for TSHA ...

       Recent Intraday Alerts

    Alert Time
    Down 1% about 6 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    1.5x Volume Pace about 10 hours ago
    Rose Above Previous Day's High about 11 hours ago
    200 DMA Resistance about 11 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    TSHA Chart by TradingView
    Basic chart:

    Profile

    Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis

    Is TSHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 1 Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit
    Jun 26 Taysha Gene Therapies announces pricing of public offering of common stock and pre-funded warrants
    Jun 26 Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    Jun 26 Biggest stock movers today: RIVN, FDX, TSHA
    Jun 26 Taysha Gene Therapies stock slides after commence securities offering to raise $75 million
    Jun 25 Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    Jun 20 Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky
    Jun 18 Taysha falls after data for Rett syndrome candidate
    Jun 18 Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
    Jun 18 Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
    See more TSHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.32
    52 Week Low 0.6154
    Average Volume 2,919,715
    200-Day Moving Average 2.38
    50-Day Moving Average 2.94
    20-Day Moving Average 3.27
    10-Day Moving Average 2.66
    Average True Range 0.34
    RSI (14) 35.90
    ADX 37.8
    +DI 16.21
    -DI 35.21
    Chandelier Exit (Long, 3 ATRs) 3.30
    Chandelier Exit (Short, 3 ATRs) 2.85
    Upper Bollinger Bands 4.74
    Lower Bollinger Band 1.80
    Percent B (%b) 0.16
    BandWidth 90.10
    MACD Line -0.26
    MACD Signal Line -0.07
    MACD Histogram -0.1863
    Fundamentals Value
    Market Cap 422.53 Million
    Num Shares 187 Million
    EPS -2.87
    Price-to-Earnings (P/E) Ratio -0.79
    Price-to-Sales 23.26
    Price-to-Book 5.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.56
    Resistance 3 (R3) 2.57 2.49 2.51
    Resistance 2 (R2) 2.49 2.41 2.48 2.49
    Resistance 1 (R1) 2.37 2.36 2.33 2.36 2.48
    Pivot Point 2.29 2.29 2.26 2.28 2.29
    Support 1 (S1) 2.17 2.21 2.13 2.16 2.04
    Support 2 (S2) 2.09 2.16 2.08 2.03
    Support 3 (S3) 1.97 2.09 2.01
    Support 4 (S4) 1.96